Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children

By  

Current Drug Metabolism, Vol. 15, Iss. 3, 2014-03 ,pp. : 251-264

Bentham Science Publishers

Access to resources Recommend Favorite

Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation

By Hassan Moustapha   Andersson Borje S  

Pharmacogenomics, Vol. 14, Iss. 1, 2013-01 ,pp. : 75-87

Future Medicine

Access to resources Recommend Favorite

High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation

By Główka Franciszek K   Romański Michał   Wachowiak Jacek  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 10, 2010-10 ,pp. : 1275-1295

Informa Healthcare

Access to resources Recommend Favorite

Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation

By ten Brink Marloes H   van Bavel Tom   Swen Jesse J   Straaten Tahar van der   Bredius Robbert GM   Lankester Arjan C   Zwaveling Juliëtte   Guchelaar Henk-Jan  

Pharmacogenomics, Vol. 14, Iss. 14, 2013-11 ,pp. : 1683-1690

Future Medicine

Access to resources Recommend Favorite

Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial

By Mohty Mohamad   Malard Florent   Blaise Didier   Milpied Noel   Furst Sabine   Tabrizi Resa   Guillaume Thierry   Vigouroux Stéphane   El-Cheikh Jean   Delaunay Jacques   Le Gouill Steven   Moreau Philippe   Labopin Myriam   Chevallier Patrice  

Cancer, Vol. 121, Iss. 4, 2015-02 ,pp. : 562-569

Blackwell Publishing

Access to resources Recommend Favorite